פרופ׳ שומרון בן-חורין
  מומחה לגסטרואנטרולוגיה
(מחלות מערכת העיכול ואנדוסקופיות)
מנהל מכון הגסטרואנטרולוגי ומנהל המעבדה הגסטרו-אימונולוגית שיבא, תל השומר

פרסומים נבחרים, מחבר מוביל:

Ben-Horin S, Farfel Z, Mouallem M.  Gastroenteritis-associated hyperamylasemia: Prevalence and clinical significance. Arch Intern Med 2002

 

Ben-Horin S, Bardan E, Barshack I, Zaks N, Livneh A.  Cholesterol crystal embolization to the digestive system: characterization of a common, yet overlooked presentation of atheroembolism. Am J Gastroenterol 2003

 

Ben-Horin S, Green PHR, Bank I, Chess L, Goldstein I.   Characterizing the circulating Gliadin-specific CD4+ memory T-cells in patients with celiac disease: Linkage between memory function, gut homing and Th1 polarization.   J Leukoc Biol 2006

 

Ben-Horin S, Bar-Meir S, Avidan B.  The impact of colon cleanliness assessment on endoscopists' recommendations for follow-up colonoscopy. Am J Gastroenterol 2007

 

Ben-Horin S, Bar-Meir S, Avidan B.  The outcome of a second preparation for colonoscopy after preparation failure in the first procedure. Gastrointest Endosc 2009

 

Ben-Horin S, Goldstein I, Fudim E, Yerushalmi Z, Picard O , Barshack IC, Bank I, Goldschmid Y, Bar Meir S, Mayer L, Chowers Y. Thiopurines' delayed-onset of the anti-inflammatory effect: Early preservation of immune effector functions followed by eventual memory cell depletion.  Gut 2009

 

Ben-Horin S, Margalit M, Bossuyt P, Maul J, Shapira Y, Bojic D, Chermesh I, Al-Rifai A, Schoepfer A, Bosani M, Allez M, Lakatos PL, Bossa F, Eser A, Stefanelli T, Carbonnel F, Katsanos K, Checchin D, Sáenz de Miera I, Chowers Y, Moran GW, for the European Crohn's and Colitis Organization (ECCO).  The impact of concomitant treatment by immuno-modulators and antibiotics on the outcome of C. difficile-associated inflammatory bowel disease exacerbation.  Clin Gastroenterol Hepatol 2009

 

Ben-Horin S, Yavzori M, Katz L, Kopylov U, Picard O, Fudim e, Coscas D, Goldstein I, Chowers Y.  The immunogenic part of infliximab is the F(ab')2 fragment, but measuring antibodies to the intact infliximab molecule is more clinically useful.  Gut 2011

 

Yanai H, Nguyen GC, Yun L,  Lebwohl O, Navaneethan U, Stone CD, Ghazi L, Moayyedi P, Brooks J, Bernstein CN, Ben-Horin S.  The practice of gastroenterologists in treating flaring IBD patients with C.difficile: Antibiotics alone or combined antibiotics-Immunomodulators ?   Inflamm Bowel Dis 2011

 

Ben-Horin S, Yavzori M, Kopylov U, Picard O, Fudim E, Eliakim R, Chowers Y, Lang A.  Detection of Infliximab in breast milk of nursing mothers with inflammatory bowel disease.  J Crohn & Colitis 2011;

 

Kopylov U,  Mantzaris GJ, Katsanos KH, Reenaers C, Ellul P, Rahier JF, Israeli E, Lakatos P, Fiorino G, Cesarini M, Tsianos E, Louis E, Ben-Horin S.   The efficacy of shortening the dosing interval to once every six weeks in Crohn's patients losing response to maintenance dose of Infliximab – A multi-center European study. Aliment Pharmacol Ther 2011

 

Ben-Horin S, Bujanover Y, Goldstein S, Nadler M, Lang A, Kopylov U, Katz L, Schwartz E, Avidan B . Travel associated health risks for patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2012

 

Ben-Horin S, Mazor Y, Yanai H, Ron Y, Kopylov U, Yavzori M, Picard O, Fudim E, Maor Y, Lahat A, Coscas D, Eliakim R, Dotan I, Chowers Y. The decline of anti-drug antibody titers after discontinuation of anti-TNFs:  Implications for predicting re-induction outcome in IBD. Aliment Pharmacol Ther 2012

 

Katz L, Gisbert JP, Manoogian B, Lin K, Steenholdt  C, Atreja A, Ron Y, Swaminath A, Mantzaris GJ, Shah S, Hart A, Lakatos PL, Ellul P, Israeli E, Svendsen  MS, van der Woude  CJ, Katsanos KH , Tsianos EV, Natha T, Abreu M, Dotan I, Lashner B, Brynkov J, Terdiman JP, Higgins PDR, Chaparro M, Ben-Horin S.  Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response   Inflamm Bowel Dis 2012

 

Ben-Horin S, Waterman M, Kopylov U, Yavzori M, Picard O, Fudim E, Awadie A, Weiss B, Chowers Y.  Elimination of detectable anti-infliximab antibodies and reversal of loss of response by the addition of an immuno-modulator.  Clin Gastroenterol Hepatol 2013

 

Ben-Horin S, Polak-Charcon S, Barshack I, Picard O, Fudim E, Yavzori M, Avivi C, Mardoukh C, Shimoni A, Chowers Y, Maor Y.  Celiac disease resolution after allogeneic bone marrow transplantation is associated with absence of Gliadin-specific memory response by donor-derived intestinal T-cells.    J Clin Immunol 2013

 

Ungar B, Chowers Y, Yavzori M, Picard O, Fudim E, Har-Noy O, Kopylov U, Elyakim R, Ben-Horin S.  The temporal evolution of anti-drug antibodies in inflammatory bowel disease patients treated with infliximab. Gut 2014

​

Yanai H, Lichtenstein L, Assa A, Mazor Y, Weiss B, Levine A, Ron Y, Kopylov U, Bujanover Y, Rosenbach Y, Ungar B, Eliakim R, Chowers Y, Shamir R, Fraser G, Dotan I, Ben-Horin S.  Levels of Drug and Anti-drug Antibodies are Associated with Outcome of Interventions after Loss of Response to Infliximab or Adalimumab. Clin Gastroenterol Heaptol 2015

 

Lang A, Salomon N, Wu JC, Kopylov U, Lahat A, Har-Noy O, Ching JY, Cheong PK, Avidan B, Gamus D, Kaimakliotis I, Eliakim R, Ng SC, Ben-Horin S. Curcumin in Combination With 5-aminosalycilate Induces Remission in Patients with Mild to Moderate Ulcerative Colitis in a Randomized Controlled Trial. Clin Gastroenterol Hepatol 2015

 

Ben-Horin S, Chowers Y, Ungar B, Kopylov U, Loebstein R, Weiss B, Eliakim R, Del Tedesco E, Paul S, Roblin X.   Undetectable anti-TNF drug levels in patients with long-term remission predict successful drug withdrawal. Aliment Pharmacol Ther 2015

 

Kopylov U, Yablecovitch D, Lahat A, Neuman S, Levhar N, Greener T, Klang E, Rozendorn N, Amitai MM, Ben-Horin S*, Eliakim R*.  Detection of Small Bowel Mucosal Healing and Deep Remission in Patients With Known Small Bowel Crohn's Disease Using biomarkers, Capsule Endoscopy, and Imaging.   Am J Gastroenterol 2015

 

Ben-Horin S, Yavzori M, Benhar I, Picard O, Fudim E, Ungar B, Lee SY, Kim SH, Eliakim R, Chowers Y Cross-immunogenicity: Antibodies to infliximab in Remicade-treated IBD patients similarly recognize the bio-similar Remsima.  Gut 2016

 

Ben-Horin S, Itzhaki Z, Haj-Natour O, Segev S, Eliakim R, Avidan B.   Rarity of Adenomatous polyps in ulcerative colitis: Implications for colonic carcinogensis.   Endoscopy 2016

 

Ungar B, Yoav Mazor, Roni Weisshof, Henit Yanai, Idan Goren, Amir Waizbard, Miri Yavzori, Ella Fudim, Orit Picard, Ronen Loebstein, Uri Kopylov, Iris Dotan, Yehuda Chowers, Rami Eliakim, Ben-Horin S. Induction infliximab levels among  patients with acute severe ulcerative colitis compared to patients with moderate-severe ulcerative colitis. Aliment Pharmacol Ther 2016

 

Ungar B, Engel T, Yablecovitch D, Lahat A, Lang A, Avidan B, Har-Noy O, Carter D, Levhar N, Selinger L, Neuman S, Natour OH, Yavzori M, Fudim E, Picard O, Kopylov U, Chowers Y, Naftali T, Broide E, Shachar E, Eliakim R, Ben-Horin S. Prospective Observational Evaluation of Time-Dependency of Adalimumab       Immunogenicity and Drug Concentrations: The POETIC Study. Am J Gastroenterol. 2018  

​

Ungar B, Kopylov U, Yavzori M, Fudim E, Picard O, Lahat A, Coscas D, Waterman M, Haj-Natour O, Orbach-Zingboim N, Mao R, Chen M, Chowers Y, Eliakim R, Ben-Horin S.  Association of Vedolizumab Level, Anti-Drug Antibodies, and alpha4beta7 Occupancy With Response in Patients With Inflammatory Bowel Diseases.  Clin Gastroenterol Hepatol. 2018 

​

Ben-Horin S, Lahat A, Amitai MM, Klang E, Yablecovitch D, Neuman S, Levhar N, Selinger L, Rozendorn N, Turner D, Chowers Y, Odes S, Schwartz D, Yanai H,  Dotan I ,Braun T, Haberman Y, Kopylov U,  Eliakim Rami.

Assessment of small bowel mucosal healing by video capsule endoscopy predicts short and long-term risk of Crohn’s disease flare: A prospective cohort study. Lancet Gastroenterol Hepatol 2019

​

Schreiber S*, Ben-Horin S*, Leszczyszyn J, Dudkowiak R, Lahat A, Gawdis-Wojnarska B, Pukitis A, Horynski M, Farkas K, Kierkus J, Kowalski M, Lee SJ, Kim SH, Suh JH, Kim MR, Lee SG, Ye BD, Reinisch W.    

Randomized Controlled Trial: Subcutaneous versus Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease. Gastroenterology 2021

 

Ungar B, Malickova K, Hanžel J, Abu-Arisha M, Paul S, Rocha C, Ben-Shatach Z, Abitbol CM, Haj-Natour O, Selinger L, Yavzori M, Fudim E, Picard O, Shoval I, Eliakim R, Kopylov U, Magro F, Roblin X, Chowers Y, Drobne D, Lukas M, Ben-Horin S.                   

Dose-optimization for loss-of-response to vedolizumab: pharmacokinetics and immune mechanisms.                                             J Crohns Colitis. 2021  

 

Klang E, Kopylov U, Mortensen B, Damholt A, Soffer S, Barash Y, Konen E, Grinman A, Yehuda RM, Buckley M, Shanahan F, Eliakim R, Ben-Horin S.

A Convolutional Neural Network Deep Learning Model Trained on CD Ulcers Images Accurately Identifies NSAID Ulcers. Front Med (Lausanne). 2021

​

Ben-Horin S*, Novack L*, Guo J, Zhao Y, Mao R, Sergienko  R, Zhang J, Kobayashi T, Hibi T, Chowers  Y, Peyrin-Biroulet L, Colombel JF, Kaplan GG, Chen MH.

Efficacy of biologic drugs in short-duration versus long-duration inflammatory bowel disease: A systematic review and an individual-patient level meta-analysis of randomized controlled trials

Gastroenterology 2022